Overview

A Study of Continuous Blood Pressure Monitoring in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2023-03-03
Target enrollment:
Participant gender:
Summary
The main purpose of this study in healthy participants is to find out whether the traditional ambulatory blood pressure monitor (ABPM) and newer wearable devices (EmbracePlus smartwatch device, Biobeat chest patch device, and Aktiia wrist device) will accurately pick up changes in blood pressure caused by 2 different medications (propranolol and pseudoephedrine). The study will last about 29 days excluding the screening period of 28 days.
Phase:
N/A
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Ephedrine
Propranolol
Pseudoephedrine